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Our aim was to explore the impact of the HER2/neu, HER3
receptor as well as their ligands’ neuregulin (NRG1)
expression on the outcome of patients with metastatic
colorectal cancer (mCRC). NRG1, HER2/neu and HER3
expression was evaluated in 208 patients with mCRC
receiving 5-FU/LV plus irinotecan or irinotecan plus
oxaliplatin as the first-line treatment. Biomarker expression
was correlated with the outcome of patients. NRG1 (low:
192 vs. high: 16), HER2/neu (low: 201 vs. high: 7) and HER3
(low: 69 vs. high: 139) expressions were assessed in 208
patients. High versus low NRG1 expression significantly
affected progression-free survival (PFS) [4.7 vs. 8.2 months,
hazard ratio (HR): 2.45; 95% confidence interval (CI):
1.45–4.13; P= 0.001], but not overall survival (OS) (15.5 vs.
20.7 months, HR: 1.33; 95% CI: 0.76–2.35; P= 0.32). High
versus low HER3 expression (PFS: 7.1 vs. 8.8 months, HR:
1.11; 95% CI: 0.82–1.50; P= 0.50; OS: 19.8 vs. 21.1 months,
HR: 0.95; 95% CI: 0.70–1.30; P= 0.75) and high compared
with low HER2/neu expression (PFS: 7.7 vs. 8.0 months, HR:
1.07; 95% CI: 0.71–1.60; P= 0.75; OS: 16.6 vs. 21.1 months,
HR: 1.13; 95% CI: 0.75–1.71; P= 0.57) did not influence
outcome. High NRG1 expression was associated with
inferior PFS in the FIRE-1 trial. We did not detect a
prognostic impact of HER2/neu and HER3 overexpression
in mCRC. The frequency of overexpression was comparable
with other studies. Anti-Cancer Drugs
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Introduction
Treatment of metastatic colorectal cancer (mCRC) has
improved since molecular biomarkers are being eval-
uated for their predictive and prognostic information,
such as RAS mutations for epidermal growth factor
receptor (EGFR)-targeted treatment [1,2]. Together with
the HER2/neu, HER3 and HER4 receptor, the EGFR
belongs to the HER receptor family [3]. These receptors
have tyrosine kinase activity. When activated, the
receptors engage intracellular signalling pathways leading
to proliferation [4–8].
HER2/neu overexpression was identified as valuable tar-
get in subpopulations of breast cancer and gastric cancer
[9–11]. The HERACLES trial has further identified
HER2/neu overexpression as a targetable structure in a
subset of patients with KRAS wild-type mCRC [12].
Besides this potential predictive relevance, the unfa-
vourable outcome of colorectal cancer (CRC) patients has
been associated with HER2/neu overexpression in pre-
vious analyses [13,14].
Potentially treatment-relevant expression of the HER3
receptor has been reported in several solid cancer types
[15]. If neuregulin (NRG1) binds to the HER3 receptor,
HER3 forms heterodimers with the HER2/neu receptor
[6]. Subsequently, the PI3K-AKT and MAPK pathways
are activated, which stimulate tumour proliferation [6,15].
In the literature, HER3 expression rates in CRC cells
range from 34 to 90% [15]. However, it is not clear if
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HER3 expression is associated with patients outcome in
colorectal cancer. HER3 overexpression was reported to
be a negative prognostic marker for patients with CRC
without distant metastases [16–18].
In addition, previous investigations focused on the role of
NRG1 in CRC as being the activating ligand of the HER3
receptor. De Boeck et al. [19] found tumour progression to
be highly influenced by bone marrow-derived mesench-
ymal stem cells releasing NRG1 in vitro and in vivo.
Furthermore, two investigations indicated a potential role
for predicting lymph node involvement and the occur-
rence of distant metastases [20–22]. Nevertheless, two
cohorts of advanced CRC and one study of a cohort of
CRC patients with distant metastases did not confirm
effects on outcome [23–25]. Coalteration ofHER2/neu and
HER3 expression was found rarely, also without impact
on the outcome of patients with CRC [23].
This analysis was designed to confirm the prevalence and
prognostic impact of HER2/neu, HER3 and NRG1
expression in a chemotherapy-based study cohort of 208
patients with mCRC (FIRE-1 trial) receiving either
5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as
first-line therapy. To our knowledge, the FIRE-1 trial is
the first randomized-controlled trial to investigate the
impact of HER2/neu and HER3 receptor overexpression
in relation to NRG1 expression [16–18,20–24].
Methods
Study design and treatment schedule
FIRE-1 was a multicentre phase III study. The protocol,
primary results and characteristics of patients have been
published previously [26]. Also, details on the sub-
population evaluable for translational research have been
reported [27]. Information on RAS mutation status and
EGFR ligand expression was available for the cohort as
described previously [27].
Patients
Our analysis included 208 of 479 patients with available
tumour material [27] for the analysis of HER2/neu, HER3
and NRG1 expression.
Ethics
The trial was conducted in accordance with the
Declaration of Helsinki (1996). All patients provided
written informed consent to be treated within a clinical
trial. This investigation was performed as a retrospective
evaluation with the approval of the local ethics committee
of the University of Munich (registry-number: 545-11).
End points
For this manuscript, overall survival (OS) (time from
randomization to death), progression-free survival (PFS)
(interval between randomization and death or progres-
sion) and response rate (WHO classification: complete
remission, partial remission, no change, progressive
disease) were used to correlate molecular characteristics
with the outcome of patients of the FIRE-1 trial.
Immunohistochemistry
Immunohistochemistry was performed using 5 μm whole
standard tissue sections of FFPE tumour samples. For
the detection of HER2/neu, a prediluted anti-HER2/neu
rabbit monoclonal antibody (clone 4B5; Ventana Medical
Systems, Oro Valley, Arizona, USA) was used as the
primary antibody. The staining was performed on a
Ventana Benchmark XT autostainer using the XT
UltraView diaminobenzidine kit (Ventana Medical
Systems) following the manufacturer’s protocols. Staining
of HER3 and NRG1 was performed using the Vectastain
ABC-Kit Elite Universal detection system (Vector
Laboratories, Peterborough, UK). For HER3 immuno-
histochemistry, a monoclonal rabbit antibody was used as
the primary antibody (ab93739; Abcam, Cambridge, UK).
NRG1 staining was performed using a polyclonal human
antibody (HPA010964; Atlas Antibodies, Stockholm,
Sweden).
Scoring of high and low expression, FISH
As no evident and standardized method for dividing high
and low expression of HER2/neu, HER3 and NRG1 exis-
ted at the time of evaluation, we used theHER2/neu score
of Rüschoff and colleagues in gastric cancer for scoring
complete biomarker expression. Therefore, membrane
staining was graduated by intensity (0: none, 1+ : weak,
2+ : moderate, 3+ : strong) and percentage of stained
tumour cells (Fig. 1). High expression was defined by a
percentage of more than 10% stained tumour cells and at
least moderate (2+ or 3+ ) membrane staining versus no
or weak staining (0 or 1+ ) for low expression. In addition,
two-colour fluorescence in-situ hybridization (FISH) was
performed in patients showing moderate (2+ ) HER2/neu
staining. Chromosome 17 centromere signals (green) as
well as HER2 gene signals (red) were counted in at least
20 nuclei of colorectal tumour cells. Thus, a red to green
ratio of at least 2 indicated amplification of HER2.
Primary tumour slides were evaluated by two indepen-
dent observers (A.S. and J.N.) using a light microscope.
Disagreements (< 5%) were reviewed together, followed
by conclusive judgement.
Statistical analysis
OS and PFS stratified by the molecular markers were
estimated using Kaplan–Meier analysis. Significant dif-
ferences were evaluated using the log-rank test and Cox
regression analysis. Univariate Cox regression was per-
formed in subgroups. The correlation of clinicopathologic
parameters with biomarker expression was assessed using
the χ2-test and the Fisher exact test for nominal variables.
All P-values of less than 0.05 (two sided) were considered
significant. SPSS PASW 18.0 (SPSS Inc., Chicago,
Illinois, USA) was used for statistical analysis.
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Results
Study population
HER2/neu, HER3 and NRG1 analyses were carried out in
208 tumours. Characteristics of the entire patient popu-
lation and the evaluable subpopulation have been pub-
lished before [27]. According to baseline and tumour
characteristics as well as PFS and OS, the subpopu-
lation was well comparable with the entire study
population [27].
Prevalence of high NRG1, HER3 and HER2/neu
expression
Of 208 metastatic colorectal tumours in total, high NRG1
expression was detected in 16 (7.7%) specimens. 139 of
208 tumours (67%) were diagnosed to have HER3 over-
expression. Twenty-three (11.1%) patients showed
moderate HER2/neu staining. A subsequent FISH ana-
lysis, however, showed a missing gene amplification in all
of these 23 patients (HER2/neu: chromosome 17 ratio
< 2.0). Therefore, only strong (3+ ) stainings in seven
(3.3%) patients were accepted as high HER2/neu
expression.
Correlation of NRG1, HER3 and HER2/neu
A significant correlation of biomarkers with each other
could not be detected for NRG1 and HER2/neu (P= 1.00)
or for NRG1 and HER3 (P= 0.41). High HER2/neu
expression also did not correlate with HER3 over-
expression (P= 0.43; Table 1).
Association of NRG1, HER3 and HER2/neu expression
with RAS mutations and EGFR-ligand expression
HER3 overexpression was significantly correlated with
the presence of RASmutations (P= 0.02; Table 2). HER3
overexpression showed a trend towards an association
Fig. 1
Immunohistochemical staining intensity of HER2/neu expression [ + : weak (a), ++ : intermediate (b), +++ : strong (c)], HER3 expression [ + : weak
(d), ++ : intermediate (e), +++ : strong (f)] and NRG1 expression [ + : weak (g), ++ : intermediate (h), +++ : strong (i)]. NRG, neuregulin.
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with high EREG expression. (P= 0.07). All other com-
binations did not show associations.
Survival analysis
High versus low NRG1 expression significantly affected
PFS (4.7 vs. 8.2 months, hazard ratio: 2.45; 95% con-
fidence interval: 1.45–4.13; P= 0.001), but not OS (15.5
vs. 20.7 months, hazard ratio: 1.33; 95% confidence
interval: 0.76–2.35; P= 0.32). HER3 and Her2/neu
expression did not influence outcome (Fig 2a–d).
Discussion
To our knowledge, the FIRE-1 trial is the first
randomized-controlled trial to investigate the impact of
HER2/neu and HER3 receptor overexpression in relation
to NRG1 expression and RAS status in mCRC [16–18,
20–24]. Previous investigations focused mostly on ana-
lysing HER2/neu and HER3 expression in advanced
colorectal or rectal tumours with patients receiving
adjuvant radiotherapy or chemotherapy [17,18,20–22].
The FIRE-1 treatment schedule consisted of 5-FU/LV
plus irinotecan or oxaliplatin plus irinotecan as first-line
therapy, following a recommended second-line therapy
with the respective crossover study regimen. With 208
patients enrolled in the analysis, our trial represents a
robust investigation [16–18,20–24].
Evaluation of HER2/neu expression has been estab-
lished in gastric cancer by Rüschoff et al. [9] using
immunohistochemical staining and FISH in inter-
mediate cases. Therefore, we decided to use these
validated methods for patients with mCRC in accor-
dance with the literature. HER3 expression was also
evaluated by immunohistochemical stainings using a
modified Rüschoff semiquantitative scoring system, as
in previous investigations, defining overexpression by
cytoplasmatic or membrane staining intensity [16,18,23,
24]. As scoring of NRG1 expression is not yet standar-
dized for any tumour type [19], we also used an adapted
Rüschoff score.
In FIRE-1, 3.3% of tumours showed high HER2/neu
expression. This compares favourably to the average
expression rate of HER2/neu in the literature of ∼ 5.0%
[12,13,23]. In FIRE-1, 67% of primary tumours showed
high HER3 expression, comparing favourably to recent
other cohorts (Seo et al. [23]: 69%; Lédel et al. [18,22]:
70%). One trial evaluating transmembrane NRG1
expression in CRC reported a frequency of high expres-
sion of 76%, in contrast to 8% in FIRE-1 [19]. However, a
standardized scoring system is missing in this case, which
may explain the discrepancy.
We attempted to correlate expression rates of HER
receptors with HER ligands (NRG1) as well as down-
stream molecules (RAS). Unlike a previous investigation,
we could not associate HER3 expression with NRG1
expression [19]. In our investigation, regular simulta-
neous expression of HER2/neu and HER3 was also not
detected, although coexpression of HER2/neu and HER3
has been described in cohort of 364 surgically resected
CRC patients [28]. The latter discrepancy might be
caused in part by the different clinical backgrounds
of patients as well as by the different diagnostic
methods used.
By contrast, in our cohort, HER3 expression correlated
with RAS mutations, although HER3 expression could
not be associated with KRAS mutations previously [21].
This observation might have resulted from a higher
number of patients enrolled in our investigation in
addition to an extended analysis of RAS mutations.
In our study, high NRG1 expression led to a significant
decrease in PFS. This finding is supported by a previous
investigation that also observed significantly worse 5-year
PFS in patients with mCRC and high NRG1 expression
[19]. Because of the small numbers of patients showing
high NRG1 expression, conclusions are limited. The
sample size of patients with HER2/neu overexpression in
our cohort does not allow for conclusions on the prog-
nostic impact. It is noteworthy that HER3 overexpression
Table 1 Correlation of HER2/neu and HER3 overexpression with
NRG1 expression and coalteration of HER2/neu and HER3
expression
Correlation of HER2/neu and HER3 overexpression with NRG1 expression
Neuregulin 1 [n (%)]




Low 185 (89.0) 16 (7.7) 201 (96.7) 1.00
High 7 (3.3) 0 (0.0) 7 (3.3)
Total 192 (92.3) 16 (7.7) 208 (100.0)
HER3
Low 62 (29.8) 7 (3.4) 69 (33.2) 0.41
High 130 (62.5) 9 (4.3) 139 (66.8)
Total 192 (92.3) 16 (7.7) 208 (100.0)
Coalteration of HER2/neu and HER3 expression
HER2/neu [n (%)]
Low High Total [n (%)] P (two sided)
HER3
Low 68 (32.7) 1 (0.5) 69 (33.2) 0.43
High 133 (64.0) 6 (2.8) 139 (66.8)
Total 201 (96.7) 7 (3.3) 208 (100.0)
P-values calculated using the χ2-test.
NRG, neuregulin.
Table 2 Correlation of HER3 expression and RAS status
HER3 [n (%)]
RAS Low High Total [n (%)] P (two sided)
Wild type 42 (20.2) 59 (28.4) 101 (48.6) 0.02
Mutation 27 (12.9) 80 (38.5) 107 (51.4)
Total 69 (33.1) 139 (66.9) 208 (100.0)
P-values calculated using the χ2-test.
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was not associated with an unfavourable outcome in
FIRE-1, although conflicting data may exist [16–18,24,
28]. However, the small number of patients enrolled in
some trials limits conclusions.
Our investigation had several strengths. FIRE-1 was a
randomized-controlled trial with irinotecan-based treat-
ment, which had a rather small likelihood of bias in
terms of the outcome and follow-up information.
Unfortunately, although 208 patients were enrolled in
this investigation, which represented a rather robust
sample size, numbers in subgroups (NRG1, Her2/neu)
became small. It might also be argued that treatment in
FIRE-1 does not comply with the latest recomm-
endations. In addition, FIRE-1, as well as previous
investigations, lacked a validation collective for a proof-
of-principle analysis. Therefore, further research is war-
ranted to evaluate prognostic effects.
Conclusion
A significant unfavourable impact on PFS was observed
in patients with mCRC with a high NRG1 expression in
the FIRE-1 trial. We did not detect a prognostic impact
of HER2/neu and HER3 overexpression in mCRC with
respect to PFS and OS.
Acknowledgments
The authors thank all patients and families, the FIRE-1
study centres and the medical staff who contributed to
patient care.
This project was supported by DKTK, the German
Cancer Consortium.
Conflicts of interest
D.P.M. received a research grant from the Weigand-
Bohnewand-Gravenhorst-Fonds for this project. For the
remaining authors there are no conflicts of interest.
Fig. 2
Outcomes according to subgroups in FIRE-1; (a): PFS of patients in FIRE-1 comparing low and high HER3 expression. (b): OS of patients in FIRE-1
comparing low and high HER3 expression. (c): PFS of patients in FIRE-1 comparing low and high NRG1 expression. (d): OS of patients in FIRE-1
comparing low and high NRG1 expression. CI, confidence interval; NRG, neuregulin; OS, overall survival; PFS, progression-free survival.
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